Zacks Investment Research announced Codexis, Inc. (NASDAQ:CDXS), boosting its target to $5.25 earlier today
- Updated: October 16, 2016
Zacks Investment Research raised the target price of Codexis, Inc. (NASDAQ:CDXS) to $5.25 reporting a possible upside of 0.20%.
Previously on 1/06/2016, H.C. Wainwright reported on Codexis, Inc. (NASDAQ:CDXS) increased the target price from $0.00 to $6.00. At the time, this indicated a possible upside of 0.42%.
Just yesterday Codexis, Inc. (NASDAQ:CDXS) traded 0.00% even at $4.38. Codexis, Inc.’s 50-day moving average is $4.27 and its 200-day moving average is $3.95. The last closing price is up 10.67% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 45,910 shares of CDXS traded hands, down from an average trading volume of 77,295
Recent Performance Chart
Codexis, Inc. has 52 week low of $2.93 and a 52 week high of $4.63 and has a market capitalization of $0.
Brief Synopsis On Codexis, Inc. (NASDAQ:CDXS)
Codexis, Inc. is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company's CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. The Company's pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and Codex Biocatalyst Panels and Kits. The fine chemicals market consists of several market verticals, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The Company also uses its technology to develop an early stage, enzyme therapeutic product candidate for the treatment of phenylketonuria (PKU) in humans through oral administration.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.